1.1.1.209: 3(or 17)alpha-hydroxysteroid dehydrogenase
This is an abbreviated version!
For detailed information about 3(or 17)alpha-hydroxysteroid dehydrogenase, go to the full flat file.
Word Map on EC 1.1.1.209
-
1.1.1.209
-
17beta-hydroxysteroids
-
testosterone
-
aldo-keto
-
3beta-hsd
-
neurosteroids
-
steroidogenesis
-
epitestosterone
-
17-ketosteroids
-
leydig
-
corticosterone
-
17alpha-hydroxysteroids
-
3alpha-hydroxysteroid
-
3beta-hydroxysteroid
-
5alpha-reductase
-
lh-stimulated
-
17alpha
- 1.1.1.209
-
17beta-hydroxysteroids
- testosterone
-
aldo-keto
- 3beta-hsd
-
neurosteroids
-
steroidogenesis
- epitestosterone
-
17-ketosteroids
- leydig
- corticosterone
- 17alpha-hydroxysteroids
-
3alpha-hydroxysteroid
-
3beta-hydroxysteroid
-
5alpha-reductase
-
lh-stimulated
-
17alpha
Reaction
Synonyms
3(17)alpha-hydroxysteroid dehydrogenase, 3beta- and 17beta-hydroxysteroid dehydrogenase, AKR1C21, dehydrogenase, 3(17)alpha-hydroxy steroid, More
ECTree
Advanced search results
Substrates Products
Substrates Products on EC 1.1.1.209 - 3(or 17)alpha-hydroxysteroid dehydrogenase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
REACTION DIAGRAM
(2Z)-2-(5-hydroxy-4,6-dimethyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-N,N-di(prop-2-en-1-yl)hydrazinecarbothioamide + NADPH + H+
3alpha-androstanediol + NADP+
-
i.e., 5alpha-dihydrotestosterone
-
-
?
(R)-1-indanol + NADP+
1-indanone + NADPH
-
37% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
(S)-1-indanole + NADP+
1-indanone + NADPH
-
7% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
1-acenaphthenol + NADP+
1-acenaphthenone + NADPH
-
10% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
21-hydroxy-5beta-pregnane-3,20-dione + NADPH
21-hydroxy-5beta-pregnane-20alpha-ol-3-one + NADP+
-
-
-
r
4-nitrobenzaldehyde + NADPH
4-nitrobenzyl alcohol + NADP+
-
58% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
5-androstene-3beta,17beta-diol + NADP+
? + NADPH
no substrate for wild-type, but substrate for mutants Y224F, Y224D, Q222D
-
-
?
5alpha-androstan-17alpha-ol-3-one + NADP+
5alpha-androstan-3,17-dione + NADPH + H+
-
-
-
?
5alpha-androstan-3alpha,17beta-diol + NAD(P)+
17beta-hydroxy-5alpha-androstan-3-one + NAD(P)H
5alpha-androstan-3alpha-ol-17-one + NADPH + H+
5alpha-androstan-3alpha-ol-17beta-ol + NADP+
-
-
-
?
5alpha-androstane-3alpha,17beta-diol + NADP+
5alpha-androstane-17beta-ol-3-one + NADPH
-
7% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
5alpha-pregnan-3alpha,20alpha-diol + NADP+
5alpha-pregnan-20alpha-ol-3-one + NADPH
-
6% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
5alpha-pregnan-3alpha,21-diol-20-one + NADP+
5alpha-pregnan-21alpha-ol-3,20-dione + NADPH
-
7% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
5alpha-pregnane-21-ol-3,20-dione + NADPH
5beta-pregnane-3alpha,21-diol-20-one + NADP+
-
75% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
5alpha-pregnane-3,20-dione + NADPH
5alpha-pregnane-3alpha-ol-20-one + NADP+
-
10% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
5beta-androstan-17beta-ol-3-one + NADPH
5beta-androstan-17beta,3alpha-diol + NADP+
-
10% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
5beta-androstane-3,17-dione + NADPH
5beta-androstan-3alpha-ol-17-one + NADP+
-
10% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
5beta-androstane-3alpha,17beta-diol + NADP+
5beta-androstane-17beta-ol-3-one + NADPH
-
11% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
5beta-androstane-3alpha-ol-17-one + NADP+
5beta-androstane-3,17-dione + NADPH
-
9% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
5beta-pregnan-3alpha,20alpha-diol + NADP+
5beta-pregnan-3-one-20alpha-ol + NADPH
-
26% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
5beta-pregnan-3alpha-ol-20-one + NADP+
5beta-pregnan-3,20-dione + NADPH
-
19% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
5beta-pregnane-20alpha-ol-3-one + NADP+
5beta-pregnane-3alpha,20alpha-diol + NADPH + H+
-
-
-
r
acenaphthenequinone + NADPH
acenaphthenehydroquinone + NADP+
-
44% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
androst-4-ene-3,17-dione + NADPH
androst-4-ene-3alpha-ol-17-one + NADP+
-
10% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
camphorquinone + NADPH + H+
camphorhydroquinone + NADP+
-
52% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
cis-1,2-dihydroxy-3,5-cyclohexadiene + NADP+
catechol + NADPH
-
60% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
cyclohex-2-ene-1-ol + NADP+
cyclohex-2-en-1-one + NADPH
-
9% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
cyclohexanone + NADPH
cyclohexanol + NADP+
-
16% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
estrone 3-sulfate + NAD(P)H
17alpha-estradiol 3-sulfate + NAD(P)+
-
-
-
?
glycolithocholic acid + NADP+
N-[(5beta)-3,24-dioxocholan-24-yl]glycine + NADPH
-
56% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
naphthalene dihydrodiol + NADP+
naphthacatechol + NADPH
-
49% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
pyridine-4-ol + NADP+
3H-pyridine-4-one + NADPH
-
75% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
testosterone + NADP+
androst-4-en-3,17-dione + NADPH + H+
mutant G225P/G226P, wild-type shows no activity with testosterone
-
-
?
estrone 3-glucuronide + NAD(P)H
-
-
-
-
?
17alpha-estradiol 3-glucuronide + NAD(P)+
estrone 3-glucuronide + NAD(P)H
-
-
-
r
5alpha-androstan-3,17-dione + NAD(P)H
-
-
-
?
3alpha-hydroxy-5alpha-androstan-17-one + NAD(P)+
5alpha-androstan-3,17-dione + NAD(P)H
-
i.e. androsterone
-
-
?
5alpha-androstan-3,17-dione + NADPH + H+
-
no substrate for wild-type, but substrate for mutants Y224F, Y224D, Q222D
-
?
5alpha-androstan-17beta-ol-3-one + NADP+
5alpha-androstan-3,17-dione + NADPH + H+
wild-type shows no activity with 5alpha-androstan-17beta-ol-3-one
-
-
?
17beta-hydroxy-5alpha-androstan-3-one + NAD(P)H
-
-
-
-
?
5alpha-androstan-3alpha,17beta-diol + NAD(P)+
17beta-hydroxy-5alpha-androstan-3-one + NAD(P)H
-
-
i.e. 5alpha-dihydrotestosterone
r
5beta-pregnane-3alpha-ol-20-one + NADP+
-
-
-
r
5beta-pregnane-3,20-dione + NADPH + H+
5beta-pregnane-3alpha-ol-20-one + NADP+
-
21% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
5beta-pregnane-20alpha-ol-3-one + NADP+
-
-
-
r
5beta-pregnane-3alpha,20alpha-diol + NADPH + H+
5beta-pregnane-20alpha-ol-3-one + NADP+
-
-
-
-
r
androst-4-en-3,17-dione + NAD(P)H + H+
-
-
-
-
?
epitestosterone + NAD(P)+
androst-4-en-3,17-dione + NAD(P)H + H+
-
-
-
r
epitestosterone + NADP+
testosterone + NADPH + H+
-
11% of activity with trans-1,2-dihydroxy-3,5-cyclohexadiene
-
?
?
-
-
the enzyme catalyses the oxidoreduction of steroid hormones such as estrogens, androgens and neurosteroids
-
-
?
additional information
?
-
a bifunctional enzyme that catalyses the oxidoreduction of the 3- and 17-hydroxy/keto groups of steroid substrates such as oestrogens, androgens and neurosteroids, 5beta-pregnane-3alpha,20alpha-diol, 21-hydroxy-5beta-pregnane-3,20-dione, and androstenedione are docked into the substrate-binding cavity and structure analysis, Lys31, Gly225 and Gly226 are important for ligand recognition and orientation in the active site, molecular-docking simulations, overview
-
-
?
additional information
?
-
-
a bifunctional enzyme that catalyses the oxidoreduction of the 3- and 17-hydroxy/keto groups of steroid substrates such as oestrogens, androgens and neurosteroids, 5beta-pregnane-3alpha,20alpha-diol, 21-hydroxy-5beta-pregnane-3,20-dione, and androstenedione are docked into the substrate-binding cavity and structure analysis, Lys31, Gly225 and Gly226 are important for ligand recognition and orientation in the active site, molecular-docking simulations, overview
-
-
?
additional information
?
-
wild-type shows no activity with testosterone and 5alpha-androstan-17beta-ol-3-one
-
-
?
additional information
?
-
-
wild-type shows no activity with testosterone and 5alpha-androstan-17beta-ol-3-one
-
-
?